- 期刊
- OpenAccess
Intravitreal Bevacizumab Treatment in a Patient with Subfoveal Choroidal Neovascularization Secondary to Choroidal Osteoma
於脈絡膜骨瘤相關之黃斑部下脈絡膜新生血管病患施與眼內注射bevacizumab（癌思停）治療－病例報告
摘要
目的：報導一例脈絡膜骨瘤相關之脈絡膜新生血管患者在接受bevacizumab（癌思停）眼內注射後獲得良好反應。 方法：病例報告：一名51歲男性，因右眼視力減退伴隨變形視求診。經視力，眼底影像紀錄、螢光眼底攝影及視網膜斷層掃描等檢查後於右眼黃斑部發現脈絡膜骨瘤相關之脈絡膜新生血管。與病患討論後施予1.25毫克之bevacizumab（癌思停）眼內注射治療。 結果：患者右眼之視力於四週後自數手指頭進步至20/30，變形視之症狀亦於四週後消失，經過六個月的追蹤後，最終視力保持在20/30。 結論：眼內注射bevacizumab（癌思停）可以治療脈絡膜骨瘤相關之脈絡膜新生血管。
關鍵字
無資料並列摘要
Purpose: To report the favorable response of choroidal neovascularization associated with choroidal osteoma to a single intravitreal injection of bevacizumab (Avastin). Methods: A 51-year-old male presented with decreased visual acuity and metamorphopsia in his right eye. Fundus photography, fluorescein angiography, indocyanine green angiography, optical coherence tomography, and visual acuity tests were performed. Under the diagnosis of classic choroidal neovascularization secondary to choroidal osteoma, the patient's right eye was treated with a single intravitreal injection of 1.25 mg bevacizumab. Results: Visual acuity in the right eye improved from counting fingers to 20/30. Resolution of both metamorphopsia and choroidal neovascularization were noted at 4 weeks post-treatment. Central foveal thickness decreased from 416 μm to 180 μm. At the final 6-month follow-up, the patient's visual acuity was maintained at 20/30 and he had experienced no complications. Conclusion: Intravitreal injection of bevacizumab can result in the regression of choroidal neovascularization secondary to choroidal osteoma.
延伸閱讀
- 郭廣慈（2010）。Bevacizumab結膜下腔注射在眼輪部幹細胞缺損模式中對於角膜新生血管與角膜結膜化的抑制效果〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2010.00657
- Wang, J. K. (2011). 單獨玻璃體內注射癌思停或合併後筋膜下注射類固醇治療糖尿病黃斑部水腫之眼底光學同調斷層掃描之變化. 中華民國眼科醫學會雜誌, 50(2), 274-282. https://doi.org/10.30048/ACTASOS.201106.0008
- Chen, Y. H., Wu, W. C., Wang, N. K., Chen, T. L., Chao, A. N., Chen, K. J., Hwang, Y. S., Chen, Y. P., Liu, L., Kuo, J. Z. C., Chang, C. J., Chuang, L. H., & Lai, C. C. (2013). 合併光動力療法與眼內注射抗血管新生藥物治療多囊性脈絡膜病變之病患：一年之成效. 中華民國眼科醫學會雜誌, 52(1), 21-31. https://www.airitilibrary.com/Article/Detail?DocID=10213120-201304-201309060003-201309060003-21-31
- Chen, H. Y., Woung, L. C., Chen, C. C., Liou, S. W., & Tseng, G. L. (2009). 眼內注射Bevacizumab治療黃斑部隱結之療效－病例報告. 中華民國眼科醫學會雜誌, 48(3), 305-311. https://doi.org/10.30048/ACTASOS.200912.0011
- Tseng, W. K., Su, I. C., Wang, I. H., & Lee, J. J. (2018). 以動脈內注射血栓溶解劑治療眼窩底骨折術後併發視網膜分支動脈阻塞及前部缺血性視神經病變的患者－個案報告及文獻回顧. 臺灣整形外科醫學會雜誌, 27(3), 231-242. https://www.airitilibrary.com/Article/Detail?DocID=a0000593-201809-201810120027-201810120027-231-242